Alzheimer’s Biotech Acumen Pharmaceuticals Prices $125M IPO Soon After Biogen’s Aduhelm Approval
Acumen Pharmaceuticals Inc has set the terms for its IPO to raise around $125 million to take ACU193, an antibody against amyloid-beta oligomers, to the end of phase 2 in Alzheimer’s disease.